Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned new fundraising through debt or equity in the transcript. IPO proceeds have already been received and largely utilized till November 2024. The company has a positive net cash flow of Rs. 341 crore and positive cash flow from operations (Rs. 71 crore for H1 September 2024). Long-term credit rating improved to AA Stable by ICRA, indicating good financial health and borrowing capacity. Management discusses ongoing investments in CAPEX and R&D funded from existing resources. No stated plans for fresh debt or equity fundraising in the near term were dis

Any current/future capex/capital investment/strategic investment?

Land acquisition for Jammu plants completed; civil works to begin shortly with commercial production expected in FY26-27. Continued investment in API R&D with over 80 scientists; Rs. 7 crore spent in H1 FY25 and a total of Rs. 30 crore till date. Significant CAPEX of around Rs. 150 crore spent in H1 FY25 to build production capability. New injectable facility in Haridwar started commercial production in Q2 with ampoule and SVP FFS lines operational; vial and lyophilized vial production to begin in Q3; LVP FFS line to be operational by Q4. Expansion of glass ampoules, FFS ampoules, and

Future growth expectations in sales/revenue/volumes?

The company expects overall growth toward a better future with positive volume trends continuing (Page 13). CDMO business saw an 11% volume decline in Q2 but is expected to stabilize and grow in H2 and FY26 (Pages 10-11). API prices, which have impacted revenues, are expected to normalize by Q3 or Q4 FY25, potentially boosting financials (Page 9). Export markets including Europe and Africa are key growth drivers, with dossiers filed and manufacturing setups underway; commercial benefits expected in a couple of fiscals, quicker ramp-up in Zambia (~18-24 months) (Pages 5, 7, 8). Trade ge

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects growth driven by new product pipelines, R&D (400 scientists), and process improvements. Anticipates volume growth in CDMO business to stabilize and grow by FY26; no loss of market share expected. API business impacted by falling prices; EBITDA breakeven now expected 6 months after Q2 FY25, possibly delayed beyond Q4 FY25. Export business (Europe, Africa, Zambia JV) expected to yield commercial benefits in next 2-3 years. Margins impacted short-term by softer API prices, but stability is expected in H2 FY25 with potential normalization in Q3/Q4. Trade generic segment being scale

Current/ Expected Orderbook/ Pending Orders?

Akums Drugs and Pharmaceuticals Limited has a robust pipeline with over 350 dossiers pending in South-East Asia, African, Middle East, and European markets. The company received more than 80 approvals in the first half of the fiscal year, indicating steady progress in order fulfillment. They are expanding their product portfolio from oral solid dosage (OSD) to injectables, with new plants being commissioned in Europe and India. Strong focus on filing dossiers in export markets, expecting commercial benefits mostly within the next 2 fiscal years, especially from Europe and Zambia. The injectabl

Akums DrugsQ2 FY25Pharmaceuticals & Biotechnology

Akums Drugs Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹813P/E: 42.3Market Cap: ₹12.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects overall growth toward a better future with positive volume trends continuing (Page 13).
CDMO business saw an 11% volume decline in Q2 but is expected to stabilize and grow in H2 and FY26 (Pages 10-11).
API prices, which have impacted revenues, are expected to normalize by Q3 or Q4 FY25, potentially boosting financials (Page 9).
Export markets including Europe and Africa are key growth drivers, with dossiers filed and manufacturing setups underway; commercial benefits expected in a couple of fiscals, quicker ramp-up in Zambia (~18-24 months) (Pages 5, 7, 8).
Trade generic business is being scaled down but expected to reach positive monthly EBITDA by H2 FY25 (Page 11).
Continuous R&D investment aims to add new products and therapies to the pipeline to drive future growth (Page 13).
Market share in CDMO business is currently stable and expected to increase with new plant capacities coming online (Pages 9-11).

Margin guidance

Category 3

Company expects growth driven by new product pipelines, R&D (400 scientists), and process improvements.
Anticipates volume growth in CDMO business to stabilize and grow by FY26; no loss of market share expected.
API business impacted by falling prices; EBITDA breakeven now expected 6 months after Q2 FY25, possibly delayed beyond Q4 FY25.
Export business (Europe, Africa, Zambia JV) expected to yield commercial benefits in next 2-3 years.
Margins impacted short-term by softer API prices, but stability is expected in H2 FY25 with potential normalization in Q3/Q4.
Trade generic segment being scaled down; expected to break even monthly by H2 FY25.
Long-term outlook positive with investments in injectables, new facilities, and new therapies such as patented sickle cell product and others.
Stakeholders including investors expected to benefit as company scales operations and market position globally.

See what Akums Drugs management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned new fundraising through debt or equity in the transcript.
IPO proceeds have already been received and largely utilized till November 2024.
The company has a positive net cash flow of Rs. 341 crore and positive cash flow from operations (Rs. 71 crore for H1 September 2024).
Long-term credit rating improved to AA Stable by ICRA, indicating good financial health and borrowing capacity.
Management discusses ongoing investments in CAPEX and R&D funded from existing resources.
No stated plans for fresh debt or equity fundraising in the near term were disclosed during the call.

Order book

Akums Drugs and Pharmaceuticals Limited has a robust pipeline with over 350 dossiers pending in South-East Asia, African, Middle East, and European markets.
The company received more than 80 approvals in the first half of the fiscal year, indicating steady progress in order fulfillment.
They are expanding their product portfolio from oral solid dosage (OSD) to injectables, with new plants being commissioned in Europe and India.
Strong focus on filing dossiers in export markets, expecting commercial benefits mostly within the next 2 fiscal years, especially from Europe and Zambia.
The injectable facility at Haridwar is being commissioned in phases, adding to future manufacturing capacity.
Approximately 26 out of the top 30 Pharma companies in India are long-standing clients, indicating strong demand and ongoing orders.
Growth initiatives in new therapies and government-linked projects also imply a growing orderbook for the future.

See what Akums Drugs management said on order book — free account, 30 seconds.

Capex plans

Yes

Land acquisition for Jammu plants completed; civil works to begin shortly with commercial production expected in FY26-27.
Continued investment in API R&D with over 80 scientists; Rs. 7 crore spent in H1 FY25 and a total of Rs. 30 crore till date.
Significant CAPEX of around Rs. 150 crore spent in H1 FY25 to build production capability.
New injectable facility in Haridwar started commercial production in Q2 with ampoule and SVP FFS lines operational; vial and lyophilized vial production to begin in Q3; LVP FFS line to be operational by Q4.
Expansion of glass ampoules, FFS ampoules, and lyophilization capacity underway to meet growing demand.
MoU signed with Government of Zambia for a joint venture to set up pharmaceutical manufacturing facility, expected to take 18-24 months to set up.
Filed 2 dossiers in Europe; building pipeline for European and other export markets.

Track Akums Drugs — get its next earnings analysis in your feed

How does Akums Drugs rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAkums Drugs

Rev 3Mar 3

See where Akums Drugs sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Akums Drugs rank in Pharmaceuticals & Biotechnology?

Compare Akums Drugs against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Akums Drugs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Akums Drugs Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Akums Drugs rank in Pharmaceuticals & Biotechnology?

Continue your research

What Akums Drugs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season